Royce & Associates LP reduced its stake in shares of Clovis Oncology, Inc. (NASDAQ:CLVS) by 24.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,000 shares of the biopharmaceutical company’s stock after selling 16,000 shares during the quarter. Royce & Associates LP owned 0.10% of Clovis Oncology worth $4,120,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in CLVS. Bank of Montreal Can raised its stake in Clovis Oncology by 284.9% during the 2nd quarter. Bank of Montreal Can now owns 2,702 shares of the biopharmaceutical company’s stock valued at $253,000 after purchasing an additional 2,000 shares during the last quarter. Aperio Group LLC increased its holdings in Clovis Oncology by 1.7% in the 2nd quarter. Aperio Group LLC now owns 5,093 shares of the biopharmaceutical company’s stock valued at $477,000 after buying an additional 83 shares during the period. Sei Investments Co. increased its holdings in Clovis Oncology by 159.9% in the 2nd quarter. Sei Investments Co. now owns 12,239 shares of the biopharmaceutical company’s stock valued at $1,146,000 after buying an additional 7,529 shares during the period. TD Asset Management Inc. increased its holdings in Clovis Oncology by 349.8% in the 2nd quarter. TD Asset Management Inc. now owns 42,852 shares of the biopharmaceutical company’s stock valued at $4,012,000 after buying an additional 33,326 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its holdings in Clovis Oncology by 8.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 189,627 shares of the biopharmaceutical company’s stock valued at $17,755,000 after buying an additional 14,961 shares during the period.

Shares of Clovis Oncology, Inc. (CLVS) opened at $64.13 on Monday. The company has a current ratio of 3.19, a quick ratio of 3.16 and a debt-to-equity ratio of 0.94. Clovis Oncology, Inc. has a fifty-two week low of $36.40 and a fifty-two week high of $99.45.

Clovis Oncology (NASDAQ:CLVS) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.18) by ($0.06). Clovis Oncology had a negative return on equity of 122.06% and a negative net margin of 947.47%. The firm had revenue of $16.81 million during the quarter, compared to the consensus estimate of $21.12 million. During the same period in the previous year, the company posted ($1.70) EPS. equities research analysts forecast that Clovis Oncology, Inc. will post -7.63 EPS for the current year.

In other news, insider Gillian C. Ivers-Read sold 3,000 shares of the company’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $63.70, for a total value of $191,100.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Thorlef Spickschen sold 4,500 shares of the company’s stock in a transaction dated Friday, December 8th. The stock was sold at an average price of $60.00, for a total transaction of $270,000.00. Following the completion of the sale, the director now directly owns 25,618 shares in the company, valued at approximately $1,537,080. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,500 shares of company stock worth $714,720. 12.50% of the stock is owned by insiders.

CLVS has been the topic of several analyst reports. Cann reissued a “hold” rating on shares of Clovis Oncology in a report on Monday, September 11th. Royal Bank of Canada initiated coverage on shares of Clovis Oncology in a report on Thursday, September 14th. They issued a “sector perform” rating and a $81.00 price target on the stock. BidaskClub raised shares of Clovis Oncology from a “strong sell” rating to a “sell” rating in a report on Saturday, December 9th. Stifel Nicolaus reissued a “buy” rating and issued a $125.00 price target on shares of Clovis Oncology in a report on Friday, November 3rd. Finally, Oppenheimer reissued a “hold” rating on shares of Clovis Oncology in a report on Tuesday, October 10th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $86.15.

TRADEMARK VIOLATION WARNING: “Clovis Oncology, Inc. (CLVS) Shares Sold by Royce & Associates LP” was originally posted by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.watchlistnews.com/clovis-oncology-inc-clvs-shares-sold-by-royce-associates-lp/1770608.html.

Clovis Oncology Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology, Inc. (NASDAQ:CLVS).

Institutional Ownership by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.